CORDIS
EU research results

CORDIS

English EN
Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response.

Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response.

Objective

Beyond the role the intestinal metagenome plays in regulating multiple physBeyond its role in regulating multiple physiological functions that impact health, the intestinal metagenome is implicated in cancer initiation, progression and responses to therapies, even for extraintestinal neoplasia. Hence, there is an urgent need to fully identify and functionally characterize minimalist commensal ecosystems relevant to cancer, with reliable and robust methods, to validate cancer-associated gut microbiome fingerprints of high clinical relevance, and to develop diagnosis tools that will become part of the oncological arsenal for the optimization and personalization of therapy. Based on retro-and pro-spective studies, with large discovery and validation cohorts enrolling >9,000 cancer patients across 10 countries, ancillary to ongoing innovative clinical trials or FDA/EMA approvals across 4 frequent cancer types, ONCOBIOME will pursue the following aims: 1/ identify and validate core or cancer-specific Gut OncoMicrobiome Signatures (GOMS) associated with cancer occurrence, prognosis, response to, or progression on, therapy (polychemotherapy, immune checkpoint inhibitors, dendritic cell vaccines) or adverse effects, 2/ decipher the functional relevance of these cancer-associated gut commensal ecosystems in the regulation of host metabolism, immunity and oncogenesis, 3/ integrate these GOMS with other oncology hallmarks (clinics, genomics, immunomics, metabolomics) 4/ design optimal companion tests, based on those integrated signatures to predict cancer occurrence and progression. With high carat interdisciplinary experts, ONCOBIOME expects to validate cancer or therapy-specific Gut OncoMicrobiome Signatures (GOMS) across breast, colorectal, melanoma and lung cancers adjusting for covariates, to unravel the mode of action of these GOMS in innovative platforms, thus lending support to the design of cancer preventive campaigns using well characterized pre-and pro-biotics.

Coordinator

INSTITUT GUSTAVE ROUSSY

Address

Rue Camille Desmoulins 39
94805 Villejuif

France

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 2 332 500

Participants (16)

Sort alphabetically

Sort by EU Contribution

Expand all

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 898 275

UNIVERSITA DEGLI STUDI DI TRENTO

Italy

EU Contribution

€ 1 502 618,75

FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI

Italy

EU Contribution

€ 223 750

Masarykova univerzita

Czechia

EU Contribution

€ 885 546,25

UNIVERSITATSKLINIKUM ERLANGEN

Germany

EU Contribution

€ 847 125

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

EU Contribution

€ 791 358,75

IIGM FOUNDATION

Italy

EU Contribution

€ 850 436,25

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

EU Contribution

€ 666 498,75

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 2 801 953,75

CENTRE HOSPITALIER DE L'UNIVERSITEDE MONTREAL

Canada

UNICANCER

France

EU Contribution

€ 431 978,75

CHARITE - UNIVERSITAETSMEDIZIN BERLIN

Germany

EU Contribution

€ 703 062,50

GBG FORSCHUNGS GMBH

Germany

EU Contribution

€ 619 312,50

HALIODX

France

EU Contribution

€ 521 322,50

EVERIMMUNE

France

EU Contribution

€ 519 000

ALGOE SA

France

EU Contribution

€ 399 812,50

Project information

Grant agreement ID: 825410

Status

Ongoing project

  • Start date

    1 January 2019

  • End date

    31 December 2023

Funded under:

H2020-EU.3.1.2.

  • Overall budget:

    € 14 994 551,25

  • EU contribution

    € 14 994 551,25

Coordinated by:

INSTITUT GUSTAVE ROUSSY

France